Foundation Medicine reported after the close of the market yesterday that its fourth quarter revenues climbed 87 percent to $9.7 million from $5.2 million in the fourth quarter of 2013, and it reported results from more than 3,750 of its cancer tests during the quarter.

The Cambridge, Mass.-based cancer genomic analysis firm launched its next-gen sequencing-based solid tumor test, FoundationOne, which screens over 200 cancer-related genes last year, and launched a second product, FoundationOne Heme, for blood-based cancers last December.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.